Kailera Therapeutics, which has raised one of the largest rounds of 2025, is planning an IPO to fund advancement of its obesity pipeline through the clinic. The planned public offering comes as the obesity field remains crowded and capital-intensive, pushing well-funded developers to secure additional runway for late-stage trials and manufacturing scale-up.